Skip to content

Advertisement

Journal of Ovarian Research

What do you think about BMC? Take part in

Open Access

Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression

  • Yuao Deng1,
  • Fang Zhao2,
  • Liu Hui3,
  • Xiuyun Li1,
  • Danyu Zhang1,
  • Wang Lin1,
  • Zhiqiang Chen4 and
  • Yingxia Ning5Email author
Journal of Ovarian Research201710:50

https://doi.org/10.1186/s13048-017-0333-4

Received: 9 February 2017

Accepted: 19 May 2017

Published: 25 July 2017

Abstract

Background

Discoidin Domain Receptor 1 (DDR1) belongs to the family of collagen receptor tyrosine kinases that confers the progression of various cancers. Aberrant expression of DDR1 was detected in several human cancers including ovarian cancer, which had been shown to increase the migration and invasion of tumor cells. However, the precise mechanisms underlying the abnormal expression of DDR1 in ovarian cancer has not been well investigated in previous studies.

Results

In this work, a negative correlation between DDR1 and a tumor suppressor miRNA, miR-199a-3p, was observed in ovarian cancer tissues. Furthermore, in vitro experimental results confirmed that miR-199a-3p decreased the expression of DDR1 via targeting the 3’UTR of DDR1 mRNA. To explore the mechanisms for miR-199a-3p silence in ovarian cancer, the methylation status of the miR-199a promoter was analyzed in ovarian epithelial or cancer cells by methylation-specific PCR and bisulphite sequencing. As expected, the miR-199a promoter was hypermethylated in ovarian cancer cells but not in normal ovarianepithelial cells. Interestingly, knockdown of DNA methyltransferase 3A (DNMT3A) notably increased miR-199a-3p level and then attenuated the expression of DDR1 in ovarian cancer cells, which suggested that DNMT3A was responsible for the miR-199a promoter hypermethylation. Phenotype experiments showed that overexpression of miR-199a-3p significantly impaired the migratory, invasive, and tumorigenic capabilities of ovarian cancer cells as well as enhanced cisplatin resistance through inhibiting DDR1 expression.

Conclusion

These findings demonstrate a critical role of miR-199a-3p/DDR1 pathway in ovarian cancer development.

Keywords

Ovarian cancermiR-199a-3pDiscoidin domain receptor 1 (DDR1)Cisplatin

Background

As one of the most common gynecological malignant tumors, ovarian cancer has become a serious problem for female healthy because of its high morbidity and mortality. However, more than 75% of women present with locally advanced or disseminated ovarian cancer at the time of diagnosis [1]. Even though standard therapies including cisplatin-based combination chemotherapy and cytoreductive surgery have been widely applied in the clinical treatment of advanced-stage ovarian cancer, the overall 5-year survival rate for metastatic ovarian cancer is only 15–30% [2, 3]. As a main cause, development of resistance to platinum results in the failure of chemotherapy during the treatment of ovarian cancer [4]. Unfortunately, the mechanisms of platinum resistance have not been clearly demonstrated in ovarian cancer. In the present study, deregulation of Discoidin Domain Receptor 1 (DDR1) in ovarian cancer was found to enhance the resistance to cisplatin.

The discoidin domain receptor, DDR1, belongs to the family of receptor tyrosine kinases (RTKs) which transmit signals into cells by providing docking sites for effector molecules in the form of phosphorylated cytoplasmic tyrosines [5]. DDRs regulate important aspects of cellular processes including proliferation, migration, adhesion, and ECM remodeling by interacting with several types of collagen [6]. In several human cancers, such as breast cancer, lung cancer, and hepatocarcinoma, dysregulated DDRs have been observed to be related with tumor development [7]. Like many other RTKs, the DDRs display a critical role in cancer progression, in part by modulating the interaction of cancer cells with collagens [7, 8]. Moreover, DDR1 was reported to decrease the sensitivity to chemotherapy and induce survival signals, which may lead to neoplasm recurrence [9, 10]. However, the molecular mechanism underlying the abnormal expression of DDR1 in ovarian cancer was not well investigated in the previous studies. Below, we discovered DDR1 as a target of miR-199a-3p, a tumor-suppressor miRNA, which was silenced by hypermethylation in ovarian cancer.

As a class of small noncoding RNAs, miRNAs target the 3’UTRs of multiple mRNAs and block translational process, which leads to gene silence. One of the gene clusters targeted by miRNAs has been proved to be associated with tumor aggressiveness [11]. Mature human miR-199a contains two derivatives: miR-199a-5p and miR-199a-3p. The same pre-miR-199a is encoded by two loci in the human genome, miR-199a-1 in chromosome 19 and miR-199a-2 in chromosome 1. miR-199a-3p functions as a tumor suppressor and inhibits tumor metastasis by repressing various oncogenes, such as mTOR,aurora kinase A, and c-MET [1214].Previous analysis have indicated that miR-199a-3p expression is inhibited in various cancer types [15, 16]. The low expression of miR-199a-3p has been previously detected in ovarian carcinoma and is significantly correlated with a poor prognosis [17].

In this study, miR-199a-3p is revealed as an upstream regulator of DDR1 which confers the malignance and cisplatin resistance of ovarian cancer. Ectopic low levels of miR-199a-3p accompanied with increased DDR1 expressions are detected in ovarian cancer cells or tissues. Further analysis suggest that downregulation of miR-199a-3p in ovarian cancer is resulted from the promoter hypermethylation of miR-199a gene. Therefore, our study indicates that aberrant methylation status in ovarian cancer breaks the inhibitory effect of miR-199a-3p on DDR1 expression and consequently promotes the malignant phenotypes of ovarian cancer.

Methods

Cell culture and reagents

Human ovarian cancer cell lines SKOV3 and HO-8910, and immortalized ovarian epithelial cell line IOSE386 were purchased from ATCC (USA) and cultured in RPMI 1640 medium (Corning, USA) supplemented with 10% fetal bovine serum at 37 °C with 5% CO2. Cisplatin and 5-Aza-dC were purchased from Sigma (USA).

Immunohistochemistry

The study has been performed with the approval of the Ethics Committee of the Shenzhen People’s Hospital. Ovarian epithelial cancer tissues were collected by needle biopsy or surgery from 115 patients at Shenzhen People’s Hospital (Shenzhen, China), the First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China), and the Twelfth People’s Hospital of Guangzhou (Guangzhou, China) from 2009 to 2012. All specimens were fixed in 10% neutral formalin, embedded in paraffin and cut into 4-μm sections for immunohistochemical staining. The EnVision™ two-step method was used (DAKO, Hamburg, Germany), as well as the following antibody: antibody against DDR1. To estimate the score for each slide, at least 10 individual fields at 200× were chosen, and 100 cancer cells were counted in each field. The immunostaining intensity was divided into four grades: 0, no expression; 1, mildly positive; 2, moderately positive; and 3, markedly positive. The proportion of positive-staining cells was divided into five grades: 0, <10%; 1, 11–25%; 2, 26–50%; 3,51–75%; and 4, >75%. The staining results were assessed and confirmed by two independent investigators blinded to the clinical data. The percentage of positivity of the tumor cells and the staining intensities were then multiplied in order to generate the IHC score, and graded as 0–6, low expression; 7–12, high expression. Cases with a discrepancy in scores were discussed to obtain a consensus.

RNA extraction and quantitative PCR

Total RNA was isolated from clinical tissue samples with a total RNA isolation kit (AP-MN-MS-RNA, Axygen, CA, USA) as described by the manufacturer. Total RNA from each cell was isolated with Trizol Reagent (Invitrogen, NY, USA) and miRNAs were isolated with microRNA Purification Kit (Norgen Biotek, Thorold Ontario, Canada), according to the manufacturer’s protocol. miRNA-specific quantitative PCR was performed with Taqman MicroRNA Assay primers (Applied Biosystems) according to the manufacturer’s instructions. The miRNA level was normalized by U6 RNA. The qPCR for mRNA was performed with SYBR Green PCR Master Mix (Applied Biosystems).

DNA methylation analysis

Methylation specific PCR (MSP)

The bisulfite conversion of genome DNA was conducted with EZ DNA Methylation-Gold Kit (Zymo Research Corporation,USA) according to the manufacturer’s instructions. The bisulfite-treated DNA was amplified with the methylation-specific primers (Forward: TCGGTCGTAATGAGAAATAGTC; Reverse: TAAACGACTCGTCGAAACA) or the unmethylated specific primers (Forward: GTTGGTTGTA ATGAGAAATAGTT; Reverse: ATAAACAACTCATCAAAACA), and the amplified products were analyzed on agarose gel and quantified by qPCR.

DNA sodium bisulfite conversion (BSP)

Specific primers for converted promoter region were used to generate PCR product (Forward: TATATTTGGAATTGTTTATAGT; Reverse: AAAAAAATATCTAACTCTTTAA). PCR products were cloned in pGEMTeasy (Promega) followed by sequencing with Sp6 primer.

Chromatin immunoprecipitation assay

Chromatin was cross-linked with 1% formaldehyde and sonicated to obtain a DNA fragment of 200–500 bp. After centrifugation, the supernatants were subjected to immunoprecipitation overnight at 4 °C with antibodies against DNMT3A or normal IgG. The DNA-protein complexes were isolated using Protein A/G PLUS-Agarose (Santa Cruz). The crosslinking was reversed and released DNA fragments were purified and quantified by QPCR using the following primer pair for miR-199a promoter (Forward:CCACATCTGGAACTGTTTAC; Reverse:AATGTCTGACTCTTTGGGGG). Three independent experiments were performed.

Wound healing assay

The indicated cells were pre-seeded in a 6-well plate. Cell monolayers were then gently scratched with a pipette tip across the entire diameter of the well. The area of denuded surface was quantified immediately after wounding and again 24 h later. Images of the wound area were captured in 6 fields using an inverted microscope.

Invasion assay

The ability of cells to invade through matrigel was measured with Boyden’s chamber technique as previously described. The invaded cells on the filters were stained with crystal violet and then counted under the microscope. A total of five fields were counted for each transwell filter.

Colony formation in soft agar

For colony formation experiment, cells were suspended in 0.3% agar and seeded into 6-well plate pre-coated with 1.0 ml of 0.6% agar. Medium was changed every 4 days for 3 weeks. The number and size of colonies were examined and data were obtained by analyzing with Image J software.

Cell cytotoxicity assay

The indicated cells were seeded in 96-wellplates and cultured for 24 h followed by cisplatin treatment at different concentrations for 24 h. Cell viability was evaluated by CCK-8 assay (Kumamoto, Japan) according to the manufacturer’s instructions.

Flow cytometric detection of apoptosis

The indicated cells were collected for detection of apoptosis using the Annexin-V-FLUOS Kit (Roche, USA) according to the manufacturer’s instructions. All of the samples were assayed in triplicate.

Statistical analysis

All statistical analyses were carried out using the SPSS 17.0 statistical software. Experimental data were presented as mean ± SD from at least three independent experiments. The data were analyzed by the 2-tailed Student’s t-test andPearson’scorrelation test. A p value < 0.05 was considered statistically significant.

Results

A negative correlation between DDR1 and miR-199a-3p in clinical ovarian cancer tissues

Consistent with the upregulation of DDR1 in other cancer types, both the mRNA and protein of DDR1 were aberrantly overexpressed in ovarian cancer tissues compared with the normal control (Fig. 1a and c). Further clinical analysis showed that high expression of DDR1 was statistically associated with lymph node metastasis, TNM stage and distant metastasis (P < 0.05) but not with age and differentiation (P > 0.05) (Table 1). And the 3-year overall survival (OS) rate of the group with DDR1 high expression was significantly lower than that of the group with DDR1 low expression (41.67% vs 74.55%, P = 0.0091) (Fig. 1b). Contrast with DDR1, miR-199a-3p was dramatically downregulated in ovarian cancer tissues (Fig. 1d). Importantly, an inverse correlation between DDR1 and miR-199a-3p was found (Fig. 1e). These data show a poor prognosis of the ovarian cancer patients with high DDR1 expression and a negative correlation between DDR1and miR-199a-3p in ovarian cancer.
Fig. 1

A negative correlation between DDR1 and miR-199a-3p was observed in clinical ovarian cancer tissues. a The representative results of DDR1 expression in human ovarian cancer tissue compared to normal, by immunohistochemical analysis. b Kaplan–Meier survival curves for the ovarian cancer patients divided by the expression of DDR1. c Relative mRNA levels of DDR1 in ovarian cancer tissues compared with normal ovarian tissues. *P < 0.05. d Relative expression of miR-199a-3p in ovarian cancer tissues compared with normal ovarian tissues. *P < 0.05. e miR-199a-3p and DDR1 mRNA expression levels inversely correlated in 20 clinical samples. Statistical analysis to evaluate correlation was performed using Pearson’s correlation analysis (r = −0.5383, P = 0.0144)

Table 1

Correlation of the expression of DDR1 with clinicopathological features in ovarian cancer tissues

 

Total

DDR1

low

high

p

  

115

55

60

 

Age

    

0.4323

 

≤ 65

53

30

23

 

>65

62

25

37

 

Differentiation

    

0.0883

 

Well differentiation

35

17

18

 

Moderate differentiation

49

23

26

 

Poorly differentiation

26

13

13

 

Undifferentiation

5

2

3

 

Lymph node metastasis

    

0.0211*

 

No

61

40

21

 

Yes

54

15

39

 

TNM stage

    

0.0073*

 

I

39

23

16

 

II

31

17

14

 

III

24

11

13

 

IV

21

4

17

 

Distant metastasis

    

0.0002*

 

M0

90

49

41

 

M1

25

6

19

 

* p value < 0.05 was considered statistically significant

miR-199a-3p reduces DDR1 expression via targeting the 3’UTR of DDR1 mRNA in ovarian cancer cells

To examine the relationship between miR-199a-3p and DDR1 in ovarian cancer, the expression levels of miR-199a-3p and DDR1 were measured in two ovarian cancer cell lines, SKOV3 and HO-8910, and a normal ovarian cell line, IOSE386. Compared with IOSE386, higher expression of DDR1 accompanied with lower miR-199a-3p level was detected in SKOV3 and HO-8910 cells (Fig. 2a and b). Furthermore, a miR-199a-3p binding site located at the 3’UTR of DDR1 mRNA was predicted using the software “TargetScanHuman 7.1” (Fig. 2c). Consistently, transfection of miR-199a-3p mimic was shown to decrease the expression of DDR1 at both mRNA and protein level in SKOV3 cells (Fig. 2d and e). In addition, miR-199a-3p inhibitor displayed a promotive effect on the mRNA and protein level of DDR1 in IOSE386 cells (Fig. f and g). More importantly, the luciferase reporter vector of DDR1 3’UTR containing a wild miR-199a-3pbinding site or a corresponding mutant site was constructed to experimentally validate the target prediction (Fig. 2c). Transfection of miR-199a-3p mimic greatly attenuated the luciferase activity of DDR13’UTR reporter in SKOV3 cells; while miR-199a-3p inhibitor strengthened the luciferase activity in IOSE386 cells (Fig. 2h and i). As expected, mutation in the miR-199a-3p binding site evidently weakened the response of luciferase activity to miR-199a-3p mimic (Fig. 2j). Taken together, miR-199a-3p decreases the expression of DDR1 by directly targeting the 3’UTR of DDR1 mRNA in ovarian cancer cells.
Fig. 2

The mRNA of DDR1 is a target of miR-199a-3p in ovarian cancer cells. a and b The expression levels of miR-199a-3p (a) and DDR1 (b) in two ovarian cancer cell lines, SKOV3 and HO-8910, and a normal ovarian cell line, IOSE386. *P < 0.05. c The putative human DDR1–3’UTR fragment containing a wild or mutant miR-199a-3p binding site was insert into the luciferase report vector pmirGLO downstream. d and e The DDR1 mRNA (d)and protein (e) levels after the transfection with miR-199a-3p mimics or negative control in SKOV3 cells. *P < 0.05. f and g The DDR1 mRNA (f)and protein (g) levels after the transfection with an anti-miRNA inhibitor specific for miR-199a-3p or negative control in IOSE386 cells. *P < 0.05. h and iLuciferase activity of DDR1 promoter after the indicated transfection in SKOV3 (h) or IOSE386 (i) cells. *P < 0.05. j Luciferase assay in the SKOV3 cells co-transfected with DDR1–3’UTRconstructs containing a wild or mutantmiR-199a-3p binding site as well as miR-199a-3p mimics or scrambled oligonucleotides as the negative control. *P < 0.05

Promoter hypermethylation leads to downregulation of miR-199a-3p in ovarian cancer

As a principal epigenetic modification, DNA hypermethylation has been reported to be associated with aberrant expression profiles of tumor suppressors, especially miRNA. Thus, the methylation status of miR-199a promoter was focused to investigate the mechanisms behind the deregulation of miR-199a-3p in ovarian cancer. Considering that miR-199a is encoded by two loci in the human genome, miR-199a-1 in Chr 19 and miR-199a-2 in Chr 1, the promoters of miR-199a at both loci were analyzed using the software ‘CpGplot’. A region (−404/−272) with high CG composition was detected upstream the transcription start site of miR-199a-1 (Fig. 3d). Therefore, the genome DNA from ovarian cancer cells or tissues was subjected to bisulfate conversion and to a subsequent methylation-specific PCR (MSP) or bisulfite genomic sequencing (BSP). MSP results showed that the methylation levels around the region (−404/−272) were increased in ovarian cancer tissues, compared with adjacent normal tissues (Fig. 3a and c). As expected, the hypermethylation was closely related with decreased miR-199a-3p and upregulation of DDR1 in the ovarian cancer specimens (Fig. 3b). Consistent with above results, high methylation levels of the region (−404/−272) were observed in ovarian cancer cells, SKOV3but not in ovarian epithelial cells, IOSE386 (Fig. 3d). Of note, treatment with a selective inhibitor of DNA methyltransferases (5-Aza-dC) reversed the hypermethylated status in SKOV3 cells (Fig. 3d). In line with this, we found that the expression of miR-199a-3p significantly increased while DDR1 were intensively downregulated after 5-Aza-dC addition, suggesting a hypermethylation mediated loss of miR-199a-3p in ovarian cancer (Fig. 3e and f). Considering that DNMT3A is primarily responsible for the 5mC maintenance, we examined the role of DNMT3A in the methylation of miR-199a promoter in ovarian cancer cells. It was found that DNMT3A knockdown disrupted its binding to the region (−404/−272), the methylation level of which was also decreased (Fig. 3g and h). Furthermore, deprivation of DNMT3A restored the expression of miR-199a-3p and resulted in a reduced DDR1 expression in ovarian cancer cells (Fig. 3i and j). In conclusion, these results suggest that the loss of miR-199-3p expression in ovarian cancer is due to promoter hypermethylation which is enhanced by DNMT3A.
Fig. 3

Promoter hypermethylation leads to downregulation of miR-199a-3p in ovarian cancer. a Representative agarose gel MSP images of two ovarian cancer cases with paired normal surrounding tissues. b miR-199a-3p and DDR1 levels in the two ovarian cancer cases of (a) were measured. *P < 0.05. c Methylation percentage of miR-199a gene in 15 ovarian cancer cases with paired normal surrounding tissues. The methylation percentage was estimated using the

following formula: methylatede(%) = 1/(1 + 2CtU-CtM). d The hypermethylation levels of miR-199a gene promoters in IOSE386, SKOV3, and 5-Aza-dC treated SKOV3 cells were determined by bisulphite DNA sequencing showing eight independent clones from each group. e Relative level of miR-199a-3p in SKOV3 and HO-8910 cells after 5-Aza-dC treatment. *P < 0.05. f The protein level of DDR1 in SKOV3 and HO-8910 cells after 5-Aza-dC treatment. g SKOV3 cells were transfected with DNMT3A siRNA or control siRNA. ChIP sample was analysed using antibodies against IgG or DNMT3A. The antibody-promoter-binding signals were analysed by quantitative PCR. *P < 0.05. h-j SKOV3 cells were transfected with DNMT3A siRNA or control siRNA. The methylation levels of miR-199a gene promoter determined by MSP analyses (h), relative levels of miR-199a-3p measured by QPCR (i), and the protein levels of DDR1 detected by western blot (j). *P < 0.05

DDR1 functions as a downstream effector of miR-199a-3p on the migration, invasion, and tumorigenicityof ovarian cancer cells

The roles of DDRs in cancer progression and metastasis were discussed in different types of tumor. So we want to elucidate whether silencing miR-199a-3p promotes the malignant phenotypes of ovarian cancer via induction of DDR1. The results of wound healing assays showed that SKOV3 cells transfected with miR-199a-3p inhibitor presented a faster closing of scratch wound, compared with the control cells. However, stable knockdown of DDR1 weakened the promotive effect of miR-199a-3p inhibitor on wound healing (Fig. 4a and b). Similarly, cell invasion assays indicated that miR-199a-3p inhibitor resulted in an increased invasion rate of SKOV3 cells compared with the control; while the invasion induced by miR-199a-3p inhibitor was impeded following inhibition of DDR1 (Fig. 4c and d). Consistently, miR-199a-3p inhibitor was found to promote the tumorigenicity of ovarian cancer cells, however, which was disrupted by DDR1 knockdown (Fig. 4e and f). These data indicate that miR-199a-3p may influence the migratory, invasive, and tumorigenic capabilities of ovarian cancer cells via regulating DDR1 expression.
Fig. 4

DDR1 functions as a downstream effector of miR-199a-3p on the migration, invasion, and tumorigenicityof ovarian cancer cells. a Photographs of the scratch wound assay after stable knockdown of DDR1 or treatment with an anti-miRNA inhibitor specific for miR-199a-3p or negative control in SKOV3 cells. b Relative wound closure rates were measured 48 h after indicated treatments for three independent experiments. *P < 0.05. c Photographs of the transwell assay after the same treatments as (a). d The numbers of invasion cells were counted 48 h after indicated treatments for three independent experiments. *P < 0.05. e Representative images of colony formation in SKOV3 cells with the same treatments as (a). f Quantification of colony formation in (e). *P < 0.05

Dysregulation of miR-199a-3p/DDR1 pathway confers the cisplatin resistance in ovarian cancer

Dysregulation of miR-199a induced resistance to platinum-based chemotherapy has been widely observed in various cancer types. Therefore, we investigated the involvement of miR-199a-3p and DDR1 in regulating cisplatin sensitivity in ovarian cancer cells. As shown, knockdown of DDR1 by siRNA significantly increased the sensitivity of SKOV3 and HO-8910 cells to cisplatin treatment (Fig. 5a and b). Next, we examined whether knockdown of DDR1was able to override the cisplatin resistance induced by miR-199a-3p inhibitor in ovarian cancer cells. The viability assay revealed that miR-199a-3p inhibitor enhanced the cisplatin resistance of SKOV3 cells without silence of DDR1 but had no evident effect on the viability of SKOV3 cells with stable knockdown of DDR1 following cisplatin treatment (Fig. 5c). Apoptosis assays indicated that miR-199a-3p inhibitor antagonized the cisplatin induced cell apoptosis while elimination of DDR1 by shRNA abrogated the suppressive effect of miR-199a-3p inhibitor on apoptosis (Fig. 5d-f). Taken together, miR-199a-3p/DDR1pathway is crucial for the resistance to cisplatin in ovarian cancer.
Fig. 5

Dysregulation of miR-199a-3p/DDR1 pathway confers the cisplatinresistance in ovarian cancer. a-c The viability of SKOV3 cells with knockdown of DDR1 (a), HO-8910 cells with knockdown of DDR1 (b), and SKOV3 cells with stable knockdown of DDR1 or miR-199a-3p inhibitor treatment (c) for 48 h were determined by the CCK-8 assay under different concentrations of cisplatin. d Cleaved PARP and caspase 3 in the SKOV3 cells with stable knockdown of DDR1 or miR-199a-3p inhibitor treatment were detected 48 h after 10 μM cisplatin addition. e Apoptosis levels of the SKOV3 cells with the same treatments as (d) were measured 48 h after 10 μM cisplatin addition. f Analysis of three independent experiments in (e). *P < 0.05

Discussion

In the previous reports, overexpression of DDR1 was shown in ovarian cancer and identified as a potential marker for high-grade ovarian cancer [18, 19]. In the present study, loss of miR-199a-3p was found to cause the ectopic high expression of DDR1 in ovarian cancer. Bioinformation analysis revealed a conserved site at the 3’UTR of DDR1 mRNA, which was targeted by miR-199a-3p. Luciferase reporter assay also confirmed that, as a receptor tyrosine kinase, DDR1 was strictly regulated by the tumor suppressor miRNA, miR-199a-3p. Interestingly, previous findings suggested that miRNA-199a-5p directly regulated the expression of DDR1 in hepatocellular carcinoma [20]. However, unlike the hypermethylation-dependent silence of miR-199a described in the present study, a recent work by Matà et al. demonstrated that IGF-I suppressed miR-199a-5p via activating PI3K/AKT signaling and consequently increased DDR1 expression in breast cancer [21]. Therefore, diverse mechanisms may be employed for regulating miR-199a/DDR1 pathway on the different cellular context. Except for miRNA interference, the studies for regulation of DDR1 expression were limited. During the EMT process of breast epithelial cells, DDR1 was found as a transcriptional target of Zeb1 [22]. Besides, ERK1/2 mediated recruitment of PEA3 to the DDR1 promoter contributed to the DDR1 expression induced by collagen I [23]. Thus, diverse regulatory factors and pathways are involved in controlling DDR1 expression in different pathological context.

DNA hypermethylation, a principal epigenetic modification occurring in CpG islands, has been shown to be associated with aberrant miRNA expression profiles in cancer [24]. Due to that the loci of miR-199a were identified at different chromosomes, the two promoters of miR-199a were firstly analyzed by bioinformation software to detect the potential CpG islands. A CpG-rich region was identified upstream the transcription start site of miR-199a-1 gene located at Chr 19. However, no classical CpG islands were found in the proximal promoter of miR-199a-2 which is located at Chr 1. Therefore, we focused on the methylation status of miR-199a-1 promoter in this study. DNA methylation analysis by MSP indicated a higher methylation level of miR-199a promoter in ovarian cancer, compared with normal tissues. More details of the methylation status at the CpG island were further studied by BSP in ovarian cancer cells. Notably, seven sequential CpGs showed a higher methylation level than others. However, in ovarian epithelial cells, a lower methylation status was observed in the seven sequential CpGs compared with others. In addition, the seven sequential CpGs but not others in the CpG island were strikingly demethylated following 5-Aza-dC treatment in ovarian cancer cells. So, it is reasonable to hypothesize that the seven CpGs may function as a core regulatory element in the CpG island. As a crucial regulator of methylation, DNMT3A mediates the epigenetic silencing of tumor suppressor genes and then contributes to the progression of cancer [25]. Several evidences showed that DNMT3A was highly expressed in various cancers including ovarian carcinoma [26]. In the present work, we found that RNAi mediated depletion of DNMT3A restored miR-199a-3p expression through the reversal of DNA hypermethylation. Interestingly, DNMT3A was identified as another target of miR-199a-3p [27]. Because of promoter hypermethylation, the reduction of miR-199a-3p may induce the upregulation of DNMT3A, which in turn enhances the hypermethylation. Thus, a positive feedback loop may display a critical role in maintaining hypermethylation status and silence of miR-199a-3p in ovarian cancer.

In this study, we found that DDR1 not only functioned as a target of miR-199a-3p but also mediated the malignant phenotypes induced by miR-199a-3p loss. In physiological conditions, DDR-mediated cell migration or adhesion is required in healthy adults. However, in cancer, DDR1 induces tumor metastasis via promoting cell migration and invasion, which is also observed in our study for ovarian cancer. As a signaling mediator, DDR1 regulates diverse downstream effectors which confer the aggressive behaviors of DDR1 in different cancers. In EMT progress, DDR1 was found to interact with α2β1 integrin receptors and activate cell signaling pathways, which increased the expression of mesenchymal markers [28]. In breast cancer, DDR1 accelerated cell migration through blocking the migration suppressor tyrosine-protein kinase (SYK) activity [29]. Accumulating evidences also showed that DDR1 functioned as an inducer of MMP2 and MMP9, which contributed to matrix components degradation during tumor invasion [3032]. Hence, the downstream factors or pathways of DDR1, which are responsible for ovarian cancer development, are worth investigating in the future.

Overactivation of miR-199a-3p/DDR1 pathway was observed in the clinical specimens of ovarian cancer, as described by highly expressed miR-199a-3p and DDR1 (Fig. 1). However, due to collogen-dependent activation of DDR1, the behaviors of DDR1 may also rely on tumor microenvironment. Therefore, in vivo experiments were widely performed to examine the roles of DDR1 and its related signaling in tumor development [33, 34]. However, based on our results which were limited to in vitro phenotypes, the effects of miR-199a-3p and DDR1 on ovarian cancer metastasis in vivo still remain unverified.

Conclusions

In summary, our findings highlight a miR-199a-3p/DDR1 pathway, the dysregulation of which leads to the migration, invasion, and chemoresistance of ovarian cancer. Furthermore, our study provides a detailed insight into the mechanism for the miR-199a-3p loss in ovarian cancer. Hypermethylation mediated silence of miR-199a-3p is confirmed to promote DDR1 expression, which is associated with a poor prognosis in patients with ovarian cancer. Therefore, more investigations are needed to explore the potential of miR-199a-3p and DDR1 as novel therapeutic targets for ovarian cancer.

Abbreviations

DDR1: 

Discoidin Domain Receptor 1

DNMT3A: 

DNA methyltransferase 3A

MSP: 

Methylation-specific PCR

BSP: 

Bisulfite genomic sequencing

SYK: 

suppressor tyrosine-protein kinase

Declarations

Acknowledgments

We would like to thank all doctors, nurses, patients, and their family members for their kindness to support our study. We thank Dr. Xinqiong Liu for participating in collecting specimens and the early stages of designing the experiments.

Funding

This work was supported by Science and Technology Planning Project of Guangdong Province (No.2014A020212428, No.2014A020211028), the Science and Technology Innovation Foundation of Shenzhen(JCYJ20150402111430645), University scientific research project of Guangzhou (No.1201410508) and National Natural Science Foundation of China (No. 81301894).

Availability of data and materials

The datasets analysed during the current study are not publicly available due to pending intellectual property review.

Authors’ contributions

YN conceived and designed the study. YD, FZ and YN performed the experiments and wrote the manuscript. YD, FZ, LH, XL and DZ analyzed and interpreted data. YD, FZ, LH, XL, WL, ZC and YN contributed reagents and materials and helped draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

No individually identified patient data are included in the manuscript.

Ethics approval and consent to participate

This study was conducted according to the Declaration of Helsinki and was approved by the Committee at Guangzhou Medical University. Written informed consent was obtained from all individual participants included in the study.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gynecology and Obstetrics, Shenzhen People’s Hospital
(2)
Department of Infectious Disease, The third people’s Hospital of Shenzhen
(3)
Department of Gynecology and Obstetrics, The Twelfth People’s Hospital of Guangzho
(4)
Department of Pathology, Shenzhen People’s Hospital
(5)
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University

References

  1. Narod S. Can advanced-stage ovarian cancer be cured? Nat rev Clin Oncol. 2016;13:255–61.View ArticlePubMedGoogle Scholar
  2. Bookman MA. Optimal primary therapy of ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i58–62.View ArticlePubMedGoogle Scholar
  3. Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2017;144:72–6.View ArticlePubMedGoogle Scholar
  4. Davis A, Tinker AV, Friedlander M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624–31.View ArticlePubMedGoogle Scholar
  5. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Rammal H, Saby C, Magnien K, Van-Gulick L, Garnotel R, Buache E, et al. Discoidin domain receptors: potential actors and targets in cancer. Front Pharmacol. 2016;7:55.PubMedPubMed CentralGoogle Scholar
  7. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis rev. 2012;31:295–321.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Pozzi A, Yurchenco PD, Iozzo RV. The nature and biology of basement membranes. Matrix Biol. 2017;57–58:1–11.Google Scholar
  9. Ongusaha PP, Kim JI, Fang L, Wong TW, Yancopoulos GD, Aaronson SA, et al. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. Embo j. 2003;22:1289–301.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler MA, Kearns P, et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood. 2013;122:4237–45.View ArticlePubMedGoogle Scholar
  11. Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol. 2014;30:266–71.View ArticlePubMedGoogle Scholar
  12. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer res. 2010;70:5184–93.View ArticlePubMedGoogle Scholar
  13. Qu Y, Huang X, Li Z, Liu J, Wu J, Chen D, et al. miR-199a-3p inhibits aurora kinase a and attenuates prostate cancer growth: new avenue for prostate cancer treatment. Am J Pathol. 2014;184:1541–9.View ArticlePubMedGoogle Scholar
  14. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015;6:11342–56.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Gao Y, Feng Y, Shen JK, Lin M, Choy E, Cote GM, et al. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci rep. 2015;5:11365.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Liu R, Liu C, Zhang D, Liu B, Chen X, Rycaj K, et al. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget. 2016;7:56628–42.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, et al. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol. 2016;27:625–34.View ArticlePubMedGoogle Scholar
  18. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer res. 2004;10:4427–36.View ArticlePubMedGoogle Scholar
  19. Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K. Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci. 2011;12:971–82.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Mata R, Palladino C, Nicolosi ML, Lo Presti AR, Malaguarnera R, Ragusa M, et al. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget. 2016;7:7683–700.View ArticlePubMedGoogle Scholar
  22. Koh M, Woo Y, Valiathan RR, Jung HY, Park SY, Kim YN, et al. Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition. Int J Cancer. 2015;136:E508–20.View ArticlePubMedGoogle Scholar
  23. Ruiz PA, Jarai G. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem. 2011;286:12912–23.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Williams M, Cheng YY, Blenkiron C, Reid G. Exploring mechanisms of MicroRNA Downregulation in cancer. Microrna. 2017;6:2–16.Google Scholar
  25. Chen BF, Chan WY. The de novo DNA methyltransferase DNMT3A in development and cancer. Epigenetics. 2014;9:669–77.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lee JY, Jeong W, Lim W, Lim CH, Bae SM, Kim J, et al. Hypermethylation and post-transcriptional regulation of DNA methyltransferases in the ovarian carcinomas of the laying hen. PLoS One. 2013;8:e61658.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Chen BF, Gu S, Suen YK, Li L, Chan WY. microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer. Epigenetics. 2014;9:119–28.View ArticlePubMedGoogle Scholar
  28. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol. 2008;180:1277–89.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Neuhaus B, Buhren S, Bock B, Alves F, Vogel WF, Kiefer F. Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors. Cell Mol Life Sci. 2011;68:3757–70.View ArticlePubMedGoogle Scholar
  30. Juin A, Di Martino J, Leitinger B, Henriet E, Gary AS, Paysan L, et al. Discoidin domain receptor 1 controls linear invadosome formation via a Cdc42-tuba pathway. J Cell Biol. 2014;207:517–33.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Castro-Sanchez L, Soto-Guzman A, Guaderrama-Diaz M, Cortes-Reynosa P, Salazar EP. Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells. Clin Exp Metastasis. 2011;28:463–77.View ArticlePubMedGoogle Scholar
  32. Miao L, Zhu S, Wang Y, Li Y, Ding J, Dai J, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med Oncol. 2013;30:626.View ArticlePubMedGoogle Scholar
  33. Xie R, Wang X, Qi G, Wu Z, Wei R, Li P, et al. DDR1 enhances invasion and metastasis of gastric cancer via epithelial-mesenchymal transition. Tumour Biol. 2016;37:12049–59.View ArticlePubMedGoogle Scholar
  34. Valencia K, Ormazabal C, Zandueta C, Luis-Ravelo D, Anton I, Pajares MJ, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer res. 2012;18:969–80.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement